Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y2R9
UPID:
RT07_HUMAN
Alternative names:
28S ribosomal protein S7, mitochondrial; bMRP-27a
Alternative UPACC:
Q9Y2R9; B2R9N5; Q53GD6
Background:
Small ribosomal subunit protein uS7m, also known as 28S ribosomal protein S7, mitochondrial and bMRP-27a, plays a crucial role in mitochondrial function. This protein is integral to the mitochondrial ribosome, where it participates in the synthesis of proteins essential for mitochondrial energy production.
Therapeutic significance:
Combined oxidative phosphorylation deficiency 34, a disease linked to mutations in the gene encoding Small ribosomal subunit protein uS7m, highlights the protein's critical role in mitochondrial health. Understanding the role of Small ribosomal subunit protein uS7m could open doors to potential therapeutic strategies for addressing mitochondrial disorders.